Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1329-1333

  Deslouches, Berthony ^a   Steckbeck, Jonathan D ^a   Craigo, Jodi K ^a   Doi, Yohei ^a   Burns, Jane L ^b   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLISTIN; UNCLASSIFIED DRUG; WLBU2; WR12; ANTIINFECTIVE AGENT; RIFAMPICIN;

ACHROMOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA COMPLEX; CONTROLLED STUDY; CROSS RESISTANCE; ENTEROBACTERIACEAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; BACTERIUM; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; RIFAMPIN;

EID: 84921894902     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03937-14     Document Type: Article

References (33)

1. Wright JD, Hassan K, Ananth CV, Herzog TJ, Lewin SN, Burke WM, Lu YS, Neugut AI, Hershman DL. 2013. Use of guideline-based antibiotic prophylaxis in women undergoing gynecologic surgery. Obstet Gynecol 122: 1145-1153. http://dx.doi.org/10.1097/AOG.0b013e3182a8a36a.
2. Luft D, Lemmen S, Geipel U, Meerbach D, Scheithauer S, Jäger M, Eckmann C, Dettenkofer M. 2012. Infection control in the operating room: preventive measures and isolation precautions in cases of multidrug resistant pathogens]. Zentralbl Chir 137:284-292. (In German.) http://dx.doi.org/10.1055/s-0031-1271525.
3. Shaffer WO, Baisden JL, Fernand R, Matz PG, North American Spine Society. 2013. An evidence-based clinical guideline for antibiotic prophylaxis in spine surgery. Spine J 13:1387-1392. http://dx.doi.org/10.1016/j .spinee.2013.06.030.
4. Rolain JM, Canton R, Cornaglia G. 2012. Emergence of antibiotic resistance: need for a new paradigm. Clin Microbiol Infect 18:615-616. http: //dx.doi.org/10.1111/j.1469-0691.2012.03902.x.
5. Il'ina TS. 2012. Mobile ISCR elements: structure, functions, and role in the emergence, increasing and spreading of blocks of bacterial genes of multiple antibiotic resistance. Mol Gen Mikrobiol Virusol (4):3-13. (In Russian.) http://dx.doi.org/10.3103/S0891416812040040.
6. Alemayehu D, Quinn J, Cook J, Kunkel M, Knirsch CA. 2012. A paradigm shift in drug development for treatment of rare multidrugresistant Gram-negative pathogens. Clin Infect Dis 55:562-567. http://dx .doi.org/10.1093/cid/cis503.
7. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
9. Bow EJ. 2013. There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother 68:492-495. http://dx.doi.org/10.1093 /jac/dks512.
10. Ho JY, Cira NJ, Crooks JA, Baeza J, Weibel DB. 2012. Rapid identification of ESKAPE bacterial strains using an autonomous microfluidic device. PLoS One 7:e41245. http://dx.doi.org/10.1371/journal.pone.0041245.
11. Pendleton JN, Gorman SP, Gilmore BF. 2013. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 11:297-308. http://dx .doi.org/10.1586/eri.13.12.
12. Tan CM, Therien AG, Lu J, Lee SH, Caron A, Gill CJ, Lebeau-Jacob C, Benton-Perdomo L, Monteiro JM, Pereira PM, Elsen NL, Wu J, Deschamps K, Petcu M, Wong S, Daigneault E, Kramer S, Liang L, Maxwell E, Claveau D, Vaillancourt J, Skorey K, Tam J, Wang H, Meredith TC, Sillaots S, Wang-Jarantow L, Ramtohul Y, Langlois E, Landry F, Reid JC, Parthasarathy G, Sharma S, Baryshnikova A, Lumb KJ, Pinho MG, Soisson SM, Roemer T. 2012. Restoring methicillin-resistant Staphylococcus aureus susceptibility to - -lactam antibiotics. Sci Transl Med 4:126ra135. http://dx.doi.org/10.1126/scitranslmed.3003592.
13. Hancock RE. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1:156-164. http://dx.doi.org/10 .1016/S1473-3099(01)00092-5.
14. Pasupuleti M, Schmidtchen A, Malmsten M. 2012. Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol 32:143-171. http://dx.doi.org/10.3109/07388551.2011.594423.
15. Phadke SM, Deslouches B, Hileman SE, Montelaro RC, Wiesenfeld HC, Mietzner TA. 2005. Antimicrobial peptides in mucosal secretions: the importance of local secretions in mitigating infection. J Nutr 135:1289-1293.
16. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238-250. http://dx.doi.org/10 .1038/nrmicro1098.
17. Mihajlovic M, Lazaridis T. 2010. Antimicrobial peptides in toroidal and cylindrical pores. Biochim Biophys Acta 1798:1485-1493. http://dx.doi .org/10.1016/j.bbamem.2010.04.004.
18. Zhang Y, Shi W, Tang S, Li J, Yin S, Gao X, Wang L, Zou L, Zhao J, Huang Y, Shan L, Gounni AS, Wu Y, Yuan F, Zhang J. 2013. The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther 15:R161. http: //dx.doi.org/10.1186/ar4344.
19. Hale JD, Hancock RE. 2007. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther 5:951-959. http://dx.doi.org/10.1586/14787210.5.6.951.
20. Deslouches B, Steckbeck JD, Craigo JK, Doi Y, Mietzner TA, Montelaro RC. 2013. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob Agents Chemother 57:2511-2521. http://dx.doi.org/10.1128/AAC.02218-12.
21. Deslouches B, Phadke SM, Lazarevic V, Cascio M, Islam K, Montelaro RC, Mietzner TA. 2005. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob Agents Chemother 49:316-322. http://dx.doi .org/10.1128/AAC.49.1.316-322.2005.
22. Deslouches B, Islam K, Craigo JK, Paranjape SM, Montelaro RC, Mietzner TA. 2005. Activity of the de novo engineered antimicrobial peptide WLBU2against Pseudomonas aeruginosa in human serum and whole blood: implicationsfor systemic applications. Antimicrob Agents Chemother 49: 3208-3216. http://dx.doi.org/10.1128/AAC.49.8.3208-3216.2005.
23. Deslouches B, Gonzalez IA, DeAlmeida D, Islam K, Steele C, Montelaro RC, Mietzner TA. 2007. De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 60:669-672. http://dx.doi.org/10.1093/jac/dkm253.
24. Paranjape SM, Lauer TW, Montelaro RC, Mietzner TA, Vij N. 2013. Modulation of proinflammatory activity by the engineered cationic antimicrobial peptide WLBU-2. F1000Res 2:36. http://dx.doi.org/10.12688 /f1000research.2-36.v1.
25. Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, Toyoda Y, Pilewski JM, Crespo M, Pasculle AW, Clancy CJ, Nguyen MH.2011. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 70:246-252. http://dx.doi.org/10.1016/j.diagmicrobio.2010.12.023.
26. Jean SS, Hsueh PR. 2011. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother 12:2145-2148. http://dx.doi.org/10.1517/14656566 .2011.599320.
27. Michalopoulos A, Falagas ME. 2008. Colistin and polymyxin B in critical care. Crit Care Clin 24:377-391, x. http://dx.doi.org/10.1016/j.ccc.2007 .12.003.
28. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock REW.2005. Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77:451-459. http://dx.doi.org/10.1189/jlb.0704380.
29. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. 2002. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 169:3883-3891. http://dx.doi.org /10.4049/jimmunol.169.7.3883.
30. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, Bánfi B, Horswill AR, Stoltz DA, McCray PB, Jr, Welsh MJ, Zabner J. 2012. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487:109-113. http://dx.doi.org/10.1038 /nature11130.
31. O'Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR, Ernst RK, Shanks RM, Doi Y. 2013. Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother 57:2103-2108. http://dx.doi.org/10.1128 /AAC.02501-12.
32. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, Moffatt JH, Nation RL, Li J, Harper M, Adler B, Boyce JD. 2012. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-1,6-Nacetylglucosamine. Antimicrob Agents Chemother 56:59-69. http://dx .doi.org/10.1128/AAC.05191-11.
33. Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P, Pohl J, Lesho EP, Weiss DS. 2013. Clinical use of colistin induces crossresistance to host antimicrobials in Acinetobacter baumannii . mBio 4:e00021-13. http://dx.doi.org/10.1128/mBio.00021-13.